Efficacy, Safety, and Tolerability of Pantoprazole Magnesium in the Treatment of Reflux Symptoms in Patients with Gastroesophageal Reflux Disease (GERD): A Prospective, Multicenter, Post-Marketing Observational Study
- 422 Downloads
To improve proton pump inhibitor effects, pharmacological modifications have been developed such as the use of enantiomer molecules (e.g., S-omeprazole, S-pantoprazole, or dexlansoprazole), or addition of NaHCO3 (for an immediate release) or magnesium (with a lower absorption for a more sustained effect).
The objective of this study was to assess the efficacy, safety, and tolerability of pantoprazole magnesium 40 mg once daily for 4 weeks, on the relief of reflux symptoms in gastroesophageal reflux disease (GERD) patients.
A phase IV, open-label, prospective, multicenter study was designed. Patients included were prescribed pantoprazole magnesium 40 mg orally once daily for 28 ± 2 days. All patients had a history of persistent or recurrent heartburn and/or acid regurgitation for at least 3 months. Effectiveness and tolerability data obtained from patients who completed a minimum of 4 weeks of pantoprazole magnesium treatment were considered for analysis.
The account of baseline characteristics and demographics of GERD symptom intensity was made by analyzing the group of 4,343 patients that fulfilled all inclusion criteria; 54 % were females (n = 2,345) and 46 % (n = 1,998) males, with a mean age of 36.2 ± 7.5 years. Severity of symptoms, assessed by the physician using the 4-point Likert scale, reduced by at least 80 % from baseline intensity after treatment in the per protocol population. In the case of the intention-to-treat population, the improvement in symptom intensity was 73 %. The number of patients that experienced any adverse events was 175/5,027 (3.48 %).
Pantoprazole magnesium is a safe, effective, and well-tolerated drug that significantly improves GERD symptoms.
KeywordsOmeprazole Clostridium Difficile Infection Pantoprazole Rabeprazole Reflux Symptom
The current study was sponsored by Nykomed, Mexico. Nykomed did not participate in the writing of this article or in the decision to submit the article for publication. José M. Remes-Troche has received consultancy honoraria from Takeda, Janssen, and AstraZeneca. Antonio Orozco-Gamiz has worked as a speaker for Takeda, GlaxoSmithKline, and Bristol-Myers Squibb. Julio César Soto-Pérez, Oscar Teramoto-Matsubara, Gualberto Mateos, Sergio Sobrino-Cossío, Miguel Morales-Arámbula, and José Luis Tamayo de la Cuesta have no conflicts of interest that are directly relevant to the content of this study.
- 5.Khan M, Santana J, Donnellan C, et al. Medical treatments in the short term management of reflux esophagitis. Cochrane Database Syst Rev. 2007;18(2):CD003244.Google Scholar
- 9.Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc. 2000;40(1):52–62.Google Scholar
- 14.Vakily M, Zhang W, Wu J, Atkinson SN, Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin. 2009;25(3):627–38.PubMedCrossRefGoogle Scholar
- 16.Health Products and Food Branch. Summary Basis of Decision (SBD): PrPANTOLOC M™. Health Canada; 2006. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2006_pantolocm_091462-eng.php. Accessed 20 Aug 2012.
- 21.Bardhan KD. Look—but also listen! ReQuest: a new dimension-oriented GERD symptom scale. Drugs Today (Barc). 2004;40(Suppl A):15–9.Google Scholar
- 22.Directive 2001/20/S of the European Parliament and of the Council of 24 April 2001 on the approximation of the laws, regulation and administrative provisions of the member states relating to the implementation of the good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Communities L/21/34 1.5.2001. http://www.eortc.be/services/doc/clinical-eu-directive-04-april-01.pdf. Accessed 12 Dec 2013.